Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97–109. https://doi.org/10.1007/s00401-007-0278-6

PubMed  Article  Google Scholar 

Salcman M, Ebert PS (1991) In vitro response of human glioblastoma and canine glioma cells to hyperthermia, radiation, and chemotherapy. Neurosurgery 29(4):526–531. https://doi.org/10.1227/00006123-199110000-00007

CAS  PubMed  Article  Google Scholar 

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. https://doi.org/10.1056/NEJMoa043330

CAS  Article  Google Scholar 

Kim H, Zheng S, Amini SS, Virk SM, Mikkelsen T, Brat DJ et al (2015) Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res 25(3):316–327

CAS  PubMed  Article  Google Scholar 

Weller M, Cloughesy T, Perry JR, Wick W (2012) Standards of care for treatment of recurrent glioblastoma—are we there yet? Neuro-Oncol 15(1):4–27. https://doi.org/10.1093/neuonc/nos273

PubMed  Article  Google Scholar 

Stupp R, Taillibert S, Kanner A, Read W, Steinberg DM, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran DD, Brem S, Hottinger AF, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z (2017) Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318(23):2306–2316. https://doi.org/10.1001/jama.2017.18718

CAS  PubMed  Article  Google Scholar 

Martinez R, Rohde V, Schackert G (2010) Different molecular patterns in glioblastoma multiforme subtypes upon recurrence. J Neuro-Oncol 96(3):321–329. https://doi.org/10.1007/s11060-009-9967-4

CAS  Article  Google Scholar 

Network CGAR (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216):1061–1068. https://doi.org/10.1038/nature07385

CAS  Article  Google Scholar 

Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN, Cancer Genome Atlas Research Network (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1):98–110. https://doi.org/10.1016/j.ccr.2009.12.020

CAS  PubMed  PubMed Central  Article  Google Scholar 

Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, deCarvalho AC, Lyu S, Li P, Li Y, Barthel F, Cho HJ, Lin YH, Satani N, Martinez-Ledesma E, Zheng S, Chang E, Gabriel Sauvé CE, Olar A, Lan ZD, Finocchiaro G, Phillips JJ, Berger MS, Gabrusiewicz KR, Wang G, Eskilsson E, Hu J, Mikkelsen T, DePinho RA, Muller F, Heimberger AB, Sulman EP, Nam DH, Verhaak RGW (2017) Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell 32(1):42–56. https://doi.org/10.1016/j.ccell.2017.12.012

CAS  PubMed  Article  Google Scholar 

Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, Ding L, Wilson RK, van den Berg D, Shen H, Bengtsson H, Neuvial P, Cope LM, Buckley J, Herman JG, Baylin SB, Laird PW, Aldape K, Cancer Genome Atlas Research Network (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17(5):510–522. https://doi.org/10.1016/j.ccr.2010.03.017

CAS  PubMed  Article  Google Scholar 

Nagy Á, Garzuly F, Padányi G, Szűcs I, Feldmann Á, Murnyák B, Hortobágyi T, Kálmán B (2019) Molecular subgroups of glioblastoma–an assessment by immunohistochemical markers. Pathol Oncol Res 25(1):21–31. https://doi.org/10.1007/s12253-017-0311-6

CAS  PubMed  Article  Google Scholar 

Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN (1996) CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 56(1):150–153

CAS  PubMed  Google Scholar 

Szerlip NJ, Pedraza A, Chakravarty D, Azim M, McGuire J, Fang Y et al (2012). Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci U.S.A 109(8), 3041–3046. https://doi.org/10.1073/pnas.1114033109

Frattini V, Trifonov V, Chan JM, Castano A, Lia M, Abate F, Keir ST, Ji AX, Zoppoli P, Niola F, Danussi C, Dolgalev I, Porrati P, Pellegatta S, Heguy A, Gupta G, Pisapia DJ, Canoll P, Bruce JN, McLendon RE, Yan H, Aldape K, Finocchiaro G, Mikkelsen T, Privé GG, Bigner DD, Lasorella A, Rabadan R, Iavarone A (2013) The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet 45(10):1141–1149. https://doi.org/10.1038/ng.2734

CAS  PubMed  Article  Google Scholar 

Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY et al (2014) Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343(6167):189–193. https://doi.org/10.1126/science.1239947

CAS  PubMed  Article  Google Scholar 

van den Bent MJ, Gao Y, Kerkhof M, Kros JM, Gorlia T, van Zwieten K, Prince J, van Duinen S, Sillevis Smitt PA, Taphoorn M, French PJ (2015) Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas. Neuro-Oncol 17(7):935–941. https://doi.org/10.1093/neuonc/nov013

CAS  PubMed  Article  Google Scholar 

Neilsen BK, Sleightholm R, McComb R, Ramkissoon SH, Ross JS, Corona RJ, Miller VA, Cooke M, Aizenberg MR (2018) Comprehensive genetic alteration profiling in primary and recurrent glioblastoma. J Neuro-Oncol 142:1–8. https://doi.org/10.1007/s11060-018-03070-2

CAS  Article  Google Scholar 

Wang J, Cazzato E, Ladewig E, Frattini V, Rosenbloom DI, Zairis S et al (2016) Clonal evolution of glioblastoma under therapy. Nat Genet 48(7):768–776. https://doi.org/10.1038/ng.3590

CAS  PubMed  Article  Google Scholar 

Kim J, Lee IH, Cho HJ, Park CK, Jung YS, Kim Y, Nam SH, Kim BS, Johnson MD, Kong DS, Seol HJ, Lee JI, Joo KM, Yoon Y, Park WY, Lee J, Park PJ, Nam DH (2015) Spatiotemporal evolution of the primary glioblastoma genome. Cancer Cell 28(3):318–328. https://doi.org/10.1016/j.ccell.2015.07.013

CAS  PubMed  Article  Google Scholar 

Muscat AM, Wong NC, Drummond KJ, Algar EM, Khasraw M, Verhaak R et al (2018) The evolutionary pattern of mutations in glioblastoma reveals therapy-mediated selection. Oncotarget 9(8):7844. https://doi.org/10.18632/oncotarget.23541

PubMed  Article  Google Scholar 

Hegi ME, Diserens AC, Gorlia T, Hamou MF, De Tribolet N, Weller M et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003. https://doi.org/10.1056/NEJMoa043331

CAS  PubMed  Article  Google Scholar 

Nagarajan RP, Zhang B, Bell RJ, Johnson BE, Olshen AB, Sundaram V et al (2014) Recurrent epimutations activate gene body promoters in primary glioblastoma. Genome Res 24(5):761–774 http://www.genome.org/cgi/doi/10.1101/gr.164707.113

CAS  PubMed  Article  Google Scholar 

de Souza CF, Sabedot TS, Malta TM, Stetson L, Morozova O, Sokolov A, Laird PW, Wiznerowicz M, Iavarone A, Snyder J, deCarvalho A, Sanborn Z, McDonald KL, Friedman WA, Tirapelli D, Poisson L, Mikkelsen T, Carlotti CG Jr, Kalkanis S, Zenklusen J, Salama SR, Barnholtz-Sloan JS, Noushmehr H (2018) A distinct DNA methylation shift in a subset of glioma CpG island methylator phenotypes during tumor recurrence. Cell Rep 23(2):637–651. https://doi.org/10.1016/j.celrep.2018.03.107

CAS  PubMed  Article  Google Scholar 

Klughammer J, Kiesel B, Roetzer T, Fortelny N, Nemc A, Nenning KH, Furtner J, Sheffield NC, Datlinger P, Peter N, Nowosielski M, Augustin M, Mischkulnig M, Ströbel T, Alpar D, Ergüner B, Senekowitsch M, Moser P, Freyschlag CF, Kerschbaumer J, Thomé C, Grams AE, Stockhammer G, Kitzwoegerer M, Oberndorfer S, Marhold F, Weis S, Trenkler J, Buchroithner J, Pichler J, Haybaeck J, Krassnig S, Mahdy Ali K, von Campe G, Payer F, Sherif C, Preiser J, Hauser T, Winkler PA, Kleindienst W, Würtz F, Brandner-Kokalj T, Stultschnig M, Schweiger S, Dieckmann K, Preusser M, Langs G, Baumann B, Knosp E, Widhalm G, Marosi C, Hainfellner JA, Woehrer A, Bock C (2018) The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space. Nat Med 24(10):1611–1624. https://doi.org/10.1038/s41591-018-0156-x

CAS  PubMed  Article  Google Scholar 

Ferreira WAS, Pinheiro DDR, Costa Junior CAD, Rodrigues-Antunes S, Araujo MD, Leao Barros MB et al (2016) An update on the epigenetics of glioblastomas. Epigenomics 8(9):1289–1305. https://doi.org/10.2217/epi-2016-0040

CAS  PubMed  Article  Google Scholar 

Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, Cahill DP, Nahed BV, Curry WT, Martuza RL, Louis DN, Rozenblatt-Rosen O, Suva ML, Regev A, Bernstein BE (2014) Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344(6190):1396–1401. https://doi.org/10.1126/science.1254257

CAS  PubMed  PubMed Central  Article  Google Scholar 

Gill BJ, Pisapia DJ, Malone HR, Goldstein H, Lei L, Sonabend A et al (2014) MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma. Proc Natl Acad Sci U.S.A 111(34):12550–12555. https://doi.org/10.1073/pnas.1405839111

CAS  PubMed  Article  Google Scholar 

Tompa M, Kalovits F, Nagy A, Kalman B (2018) Contribution of the Wnt pathway to defining biology of glioblastoma. NeuroMolecular Med 20:1–15. https://doi.org/10.1007/s12017-018-8514-x

CAS  Article  Google Scholar 

Birbrair A, Sattiraju A, Zhu D, Zulato G, Batista I, Nguyen VT, Messi ML, Solingapuram Sai KK, Marini FC, Delbono O, Mintz A (2017) Novel peripherally derived neural-like stem cells as therapeutic carriers for treating glioblastomas. Stem Cells Transl Med 6(2):471–481. https://doi.org/10.5966/sctm.2016-0007

CAS  PubMed  Article  Google Scholar 

Orzan F, De Bacco F, Crisafulli G, Pellegatta S, Mussolin B, Siravegna G et al (2017) Genetic evolution of glioblastoma stem-like cells from primary to recurrent tumor. Stem Cells 35(11):2218–2228. https://doi.org/10.1002/stem.2703

CAS  PubMed  Article  Google Scholar 

Marucci G, Fabbri PV, Morandi L, De Biase D, Di Oto E, Tallini G et al (2015) Pathological spectrum in recurrences of glioblastoma multiforme. Pathologica 107(1):1–8

CAS  PubMed  Google Scholar 

Stark AM, Witzel P, Strege RJ, Hugo HH, Mehdorn HM (2003) p53, mdm2, EGFR, and msh2 expression in paired initial and recurrent glioblastoma multiforme. J Neurol Neurosurg Psychiatry 74(6):779–783. https://doi.org/10.1136/jnnp.74.6.779

CAS  PubMed  Article  Google Scholar